|
27 Sep 2025 |
Healthcare Global
|
Consensus Share Price Target
|
647.40 |
692.71 |
- |
7.00 |
buy
|
|
|
|
|
12 Aug 2022
|
Healthcare Global
|
Axis Direct
|
647.40
|
330.00
|
285.25
(126.96%)
|
Target met |
Buy
|
|
|
We recommend BUY with a target price of Rs 330.
|
|
12 Aug 2022
|
Healthcare Global
|
ICICI Direct
|
647.40
|
345.00
|
285.25
(126.96%)
|
Target met |
Buy
|
|
|
|
|
11 Aug 2022
|
Healthcare Global
|
Prabhudas Lilladhar
|
647.40
|
358.00
|
285.25
(126.96%)
|
|
Buy
|
|
|
|
|
11 Aug 2022
|
Healthcare Global
|
ICICI Securities Limited
|
647.40
|
339.00
|
284.20
(127.80%)
|
Target met |
Buy
|
|
|
HealthCare Global Enterprises’ (HCG) Q1FY23 performance was ahead of our estimates.
|
|
30 May 2022
|
Healthcare Global
|
Prabhudas Lilladhar
|
647.40
|
347.00
|
280.85
(130.51%)
|
|
Buy
|
|
|
|
|
27 May 2022
|
Healthcare Global
|
Axis Direct
|
647.40
|
330.00
|
276.00
(134.57%)
|
|
Buy
|
|
|
We recommend BUY with a target price of Rs 330.
|
|
28 Mar 2022
|
Healthcare Global
|
Axis Direct
|
647.40
|
330.00
|
267.70
(141.84%)
|
|
Buy
|
|
|
We recommend BUY with a TP of Rs 330/share.
|
|
14 Mar 2022
|
Healthcare Global
|
Geojit BNP Paribas
|
647.40
|
294.00
|
254.65
(154.23%)
|
Target met |
Accumulate
|
|
|
Healthcare Global Enterprises Ltd is one of India's leading oncology treatment specialists with presence across the country. HCG reported robust revenues in Q3FY22 growing by 31% YoY to Rs.358 cr during the quarter with secular growth across regions and...
|
|
11 Feb 2022
|
Healthcare Global
|
Axis Direct
|
647.40
|
330.00
|
242.50
(166.97%)
|
|
Buy
|
|
|
We recommend BUY with a target price of Rs 330.
|
|
03 Jan 2022
|
Healthcare Global
|
Axis Direct
|
647.40
|
267.00
|
245.05
(164.19%)
|
Target met |
Buy
|
|
|
We recommend a BUY on Healthcare Global Enterprises Ltd with a Target Price of Rs 267, an upside of 10% from CMP of Rs 243 and Stop Loss Rs 230.
|